Table 4.
Baseline characteristic and clinical outcomes according to treatment strategy of each etiology of ICA occlusion
| Variable | Atherosclerotic ICA occlusion group (n=43) |
Non-atherosclerotic ICA occlusion group (n=38) |
p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Medical Treatment (n=21) | EVT (n=22) | p-value | Overall | Medical Treatment (n=9) | EVT (n=29) | p-value | ||
| Baseline NIHSS | 13 (9–19) | 11 (7.5–14.5) | 16.5 (10–20) | 0.027* | 16.5 (13.75–20.25) | 18 (14.5–22) | 16 (12–20) | 0.276* | 0.011* |
| ASPECTS DWI | 9 (7–10) | 9 (8–10) | 8 (7–10) | 0.148* | 9 (8–10) | 9 (8–9.5) | 9 (9–10) | 0.248* | 0.143* |
| NIHSS 1 day | 9 (5–13) | 7 (3–12) | 11 (6.75–15.5) | 0.051* | 14 (10.5–18.0) | 14 (12.5–17) | 14 (5.5–18) | 0.667* | 0.015* |
| NIHSS 7 day | 7 (3–13) | 8 (3–12.5) | 7 (2.75–15.25) | 0.922* | 10 (5.5–15.5) | 13 (6.5–21.5) | 10 (2–15) | 0.524* | 0.195* |
| END | 7 (16.3) | 5 (23.8) | 2 (9.1) | 0.240† | 6 (15.8) | 2 (22.2) | 4 (13.8) | <0.613† | 0.952 |
| ENI | 24 (55.8) | 10 (47.6) | 14 (63.6) | 0.364† | 23 (60.5) | 5 (55.6) | 18 (62.1) | <0.999† | 0.668 |
| mRS 0–2 at 3 months | 25 (58.1) | 11 (52.4) | 14 (63.6) | 0.455 | 15 (39.5) | 2 (22.2) | 13 (44.8) | 0.273† | 0.094 |
| Mortality | 4 (9.3) | 3 (14.3) | 1 (4.5) | 0.345† | 4 (10.5) | 1 (11.1) | 3 (10.3) | <0.999† | >0.999† |
Values are presented as median (interquartile range) or number (%).
*
Mann whitney U test.
†
Fischer’s exact T test.
ICA : internal carotid artery, EVT : endovascular treatment, NIHSS : National Institute of Health Stroke Scale, ASPECTS : Alberta Stroke Program Early CT score, DWI : diffusion-weighted imaging, END : early neurological deterioration, ENI : early neurological improvement, mRS : modified Rankin Scale